3888-65-1

Basic information

• Product Name: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE
• Synonyms: 4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE;4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE HYDROCHLORIDE;4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL;4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE;4-(FLUOROPHENYL)-4-HYDROXYLPIPERIDINE HYDROCHLORIDE;4-(FLUOROPHENYL)-4-HYDROXYPIPERIDINE;4-(FLUOROPHENYL)-4-HYDROXYPIPERIDINE HYDROCHLORIDE;4-(p-Fluorophenyl)-4-piperidinol
• CAS NO: 3888-65-1
• Molecular Formula: C₁₁H₁₄FNO
• Molecular Weight: 195.24
• EINECS: 223-431-8
• Mol File: 3888-65-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 116.4-117.6℃
• Boiling Point: 313.4 °C at 760 mmHg
• Flash Point: 143.3 °C
• Appearance: /Solid
• Density: 1.173 g/cm³
• Vapor Pressure: 0.000212mmHg at 25°C
• CAS DataBase Reference: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(3888-65-1)
• EPA Substance Registry System: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(3888-65-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 3888-65-1(Hazardous Substances Data)

Usage

Uses

4-(4-Fluorophenyl)-4-piperidinol serves as one of the reagents for the discovery of AZD3514 as androgen receptor down regulator for treatment of advanced prostrate cancer. Also functions as an intermediate in the synthesis of haloperidol (H103700), an antidyskinetic; antipsychotic. neuroprotective product.

InChI:InChI=1/C11H14FNO.ClH/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11;/h1-4,13-14H,5-8H2;1H

Upstream product

• 710-90-7 4-Brom-4-(4-fluor-phenyl)-piperidin 
• 82387-58-4 1-(Ethoxycarbonyl)-4-(4-fluorophenyl)piperidin-4-ol 
• 352-13-6 4-flourophenylmagnesium bromide 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 553631-05-3 tert-butyl 4-hydroxy-4-(4-fluorophenyl)-1-piperidinecarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 163631-02-5 1-benzyl-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 803-45-2 4-<4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl>-1-(4-fluorophenyl)-1-butanone 
• 95948-65-5 SGT₅₄₂ 
• 96122-83-7 1-<2-(4-bromo-4'-fluorobenzhydryloxy)ethyl>-4-(4-fluorophenyl)piperidin-4-ol 
• 82387-49-3 1-Cinnamyl-4-<4-(4-fluorophenyl)-4-hydroxypiperidino>acetylpiperazine 
• 143017-40-7 1-<3,3-(ethylenedioxy)propyl>-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 1026235-61-9 2-[4-(4-Fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 171721-15-6 7-Benzyloxy-3-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-chromen-4-one 
• 178375-65-0 7-benzyloxy-6-fluoro-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chromen-4-one 
• 256951-86-7 {3-[4-(4-fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-propyl}-carbamic acid tert-butyl ester 
• 952579-61-2 C₁₆H₂₃FN₂O₃ 
• 178375-24-1 1-(3-methyl-4-triisopropylsilyloxyphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-one 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.